RADNOR, Pa., Jan. 4, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. ("Kyverna") (NASDAQ: KYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna's February 8, 2024 initial public offering ("IPO"). The lead plaintiff deadline is February 7, 2025.CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:If you suffered Kyverna losses, you ...

NEW YORK, Jan. 3, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Kyverna Therapeutics, Inc. ("Kyverna Therapeutics, Inc." or the "Company") (NASDAQ: KYTX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Kyverna Therapeutics, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all those who purchased or otherwise acquired Kyverna common stock pursuant and/or traceable to the Company's of ...

NEW YORK, Dec. 30, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX).Shareholders who purchased shares of KYTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/kyverna-therapeutics-inc-loss-submission-form/?id=118959&from=4 CLASS PERIOD: ...

Core Viewpoint - The Kyverna class action lawsuit alleges that the company's IPO offering documents were materially false and misleading, failing to disclose adverse data related to clinical trials, which negatively impacted the company's future operating results and share price [2][8]. Group 1: Lawsuit Details - The lawsuit, titled Rondini v. Kyverna Therapeutics, Inc., charges Kyverna and certain executives and underwriters with violations of the Securities Act of 1933 [6]. - Investors who purchased or acquired Kyverna common stock during the IPO, which took place on February 8, 2024, have until February 7, 2025, to seek appointment as lead plaintiff [6]. - The IPO involved the offering of 14.5 million shares at a price of $22.00 per share, resulting in net proceeds of approximately $296 million for Kyverna [7]. Group 2: Impact of Adverse Data - On June 14, 2024, Kyverna disclosed adverse data regarding one of its clinical trials, leading to a significant decline in share price [8]. - By the time the class action lawsuit commenced, Kyverna's stock had fallen to as low as $3.92, representing a decline of over 82% from the IPO price [8].

RADNOR, Pa., Dec. 27, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. ("Kyverna") (NASDAQ: KYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna's February 8, 2024 initial public offering ("IPO"). The lead plaintiff deadline is February 7, 2025.CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:If you suffered Kyverna losses, you ...

NEW YORK, Dec. 27, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Kyverna Therapeutics, Inc. ("Kyverna Therapeutics, Inc." or the "Company") (NASDAQ: KYTX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Kyverna Therapeutics, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all those who purchased or otherwise acquired Kyverna common stock pursuant and/or traceable to the Company's o ...

SAN DIEGO, Dec. 26, 2024 /PRNewswire/ -- Robbins LLP reminds investors that a shareholder filed a class action against Kyverna Therapeutics, Inc. (NASDAQ: KYTX) and certain of the Company's senior executives and directors who signed the Registration Statement, effective February 7, 2024, issued in connection with the Company's initial public offering ("IPO"). Kyverna is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases.For more in ...

RADNOR, Pa., Dec. 26, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Kyverna Therapeutics, Inc. (“Kyverna”) (NASDAQ: KYTX) on behalf of those who purchased Kyverna common stock pursuant and/or traceable to Kyverna’s February 8, 2024 initial public offering (”IPO”). The lead plaintiff deadline is February 7, 202 ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Kyverna Therapeutics, Inc. common stock during its IPO on February 8, 2024, about the upcoming lead plaintiff deadline of February 7, 2025 [1] Group 1: Class Action Information - Investors who bought Kyverna common stock may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6] - To serve as lead plaintiff, individuals must file a motion with the Court by February 7, 2025 [3] Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [4] Group 3: Case Details - The lawsuit claims that Kyverna's IPO registration statement and prospectus contained misstatements and omissions regarding the clinical trial results of its lead product candidate, KYV-101 [5] - Kyverna allegedly highlighted patient "improvement" while failing to disclose adverse data known at the time of the IPO, leading to investor damages when the true information became public [5]

NEW YORK, Dec. 26, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX).Shareholders who purchased shares of KYTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/kyverna-therapeutics-inc-loss-submission-form/?id=118168&from=4 CLASS PERIOD: ...